Comparative Pharmacology
Head-to-head clinical analysis: HYDELTRASOL versus PREDNISONE.
Head-to-head clinical analysis: HYDELTRASOL versus PREDNISONE.
HYDELTRASOL vs PREDNISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.
None Documented
None Documented
Clinical Note
moderatePrednisone + Digoxin
"Prednisone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePrednisone + Digitoxin
"Prednisone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePrednisone + Deslanoside
"Prednisone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePrednisone + Acetyldigitoxin
"Prednisone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Terminal half-life: 2-3 hours (plasma); clinical effects persist for 12-36 hours due to intracellular actions and active metabolite prednisolone (half-life 3-4 hours).
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Renal: <10% as unchanged drug; hepatic metabolism to inactive glucuronide and sulfate conjugates; fecal: ~20-30% via biliary elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid